Intrepid Automation and Rapid Fluidics partner to scale microfluidic manufacturing in the US
The collaboration shortens timelines and helps customers move from lab concept to compliant, high-volume production for healthcare and industrial applications
18 Feb 2026
Intrepid Automation, provider of industrial additive manufacturing (AM) solutions, and Rapid Fluidics, market leader in design and rapid-production services to microfluidic systems customers, have announced a strategic partnership to advance the development and US-based manufacturing of microfluidic technologies.
The collaboration combines Rapid Fluidics' design and prototyping expertise with Intrepid Automation's scalable, production-grade additive manufacturing capabilities, enabling more cost-effective development and production of high-precision microfluidic components.
Under the agreement, Intrepid Automation will serve as Rapid Fluidics' exclusive US manufacturing partner for microfluidics, with both companies scaling up applications in the healthcare and industrial markets. Both companies will leverage Intrepid's ISO 13485- and ISO 9001-certified facilities, combining regulatory compliance with scalable production to deliver high-quality microfluidic components.
The partnership helps close the gap between lab-scale microfluidic innovation and the requirements of US manufacturing, providing customers with a clearer path from early design to compliant, high-volume production.
"Rapid Fluidics brings deep expertise in microfluidics, and our scalable 3D printing systems allow those innovations to reach mass production without compromise," said Ben Wynne, President and CTO of Intrepid Automation. "This partnership isn't just about speed, but rather quality, regulatory compliance, and creating a foundation for future growth in several sectors, from healthcare to industrial applications."
"Partnering with Intrepid gives us the ability to bring our microfluidic designs from the lab to real-world production faster than ever," said Paul Marshall, Founder and CEO of Rapid Fluidics.
"By establishing US-based manufacturing, we can reduce costs, improve reliability, and deliver solutions that meet the growing demand for high-throughput health and industrial applications. At the end of the day, the ultimate goal is to accelerate product development and apply breakthrough microfluidic technology in ways that meaningfully improve human health," he added.